Annexon (ANNX) Accounts Payables (2019 - 2026)
Annexon (ANNX) posted quarterly Accounts Payables of $17.5 million for Q1 2026, up 67.95% year-over-year from $10.4 million in Q1 2025, and up 17.4% quarter-over-quarter from $14.9 million in Q4 2025.
Annexon (ANNX) Accounts Payables (2019 - 2026) Analysis & Trends
Annexon's Accounts Payables history runs 8 years deep, the most recent figure standing at $17.5 million for Q1 2026.
- In Q1 2026, Accounts Payables rose 67.95% year-over-year to $17.5 million; the TTM figure through Mar 2026 stood at $17.5 million (up 67.95% YoY), while the FY2025 annual figure was $14.9 million, up 43.21% from the prior year.
- Accounts Payables for Q1 2026 stood at $17.5 million, up from $14.9 million in the prior quarter.
- The five-year high for Accounts Payables was $18.2 million in Q3 2025, with the low at $4.0 million in Q1 2024.
- The 5-year median for Accounts Payables is $9.4 million (2022), against an average of $9.4 million.
- The sharpest annual moves came in 2024 and 2025: Accounts Payables sank 61.61% in 2024, then surged 179.08% in 2025.
- Annexon's Accounts Payables stood at $7.4 million in 2022, then retreated by 26.01% to $5.5 million in 2023, then jumped by 90.01% to $10.4 million in 2024, then surged by 43.21% to $14.9 million in 2025, then climbed by 17.4% to $17.5 million in 2026.
- Business Quant data shows ANNX's Accounts Payables at $17.5 million in Q1 2026, $14.9 million in Q4 2025, and $18.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Annexon | 1.00 Bn | 1.00 Bn | - | 15.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 15.73 Mn |
| Mar 31, 2026 | 17.53 Mn |
| Dec 31, 2025 | 14.93 Mn |
| Sep 30, 2025 | 18.22 Mn |
| Jun 30, 2025 | 11.52 Mn |
| Mar 31, 2025 | 10.44 Mn |
| Dec 31, 2024 | 10.43 Mn |
| Sep 30, 2024 | 6.75 Mn |
| Jun 30, 2024 | 4.13 Mn |
| Mar 31, 2024 | 3.97 Mn |
| Dec 31, 2023 | 5.49 Mn |
| Sep 30, 2023 | 4.81 Mn |
| Jun 30, 2023 | 7.16 Mn |
| Mar 31, 2023 | 10.35 Mn |
| Dec 31, 2022 | 7.42 Mn |
| Sep 30, 2022 | 6.92 Mn |
| Jun 30, 2022 | 10.30 Mn |
| Mar 31, 2022 | 9.38 Mn |
| Dec 31, 2021 | 11.15 Mn |
| Sep 30, 2021 | 4.80 Mn |